Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) FCF Margin (2024 - 2026)

Prelude Therapeutics' FCF Margin history spans 3 years, with the latest figure at 473.47% for Q1 2026.

  • On a quarterly basis, FCF Margin changed N/A to 473.47% in Q1 2026 year-over-year; TTM through Mar 2026 was 261.82%, a N/A change, with the full-year FY2025 number at 464.32%, up 100565.0% from a year prior.
  • FCF Margin hit 473.47% in Q1 2026 for Prelude Therapeutics, down from 409.91% in the prior quarter.
  • Over the last five years, FCF Margin for PRLD hit a ceiling of 409.91% in Q4 2025 and a floor of 911.97% in Q3 2024.
  • Historically, FCF Margin has averaged 354.14% across 3 years, with a median of 473.47% in 2026.
  • The widest YoY moves for FCF Margin: up 91099bps in 2025, down 61789bps in 2025.
  • Tracing PRLD's FCF Margin over 3 years: stood at 501.08% in 2024, then surged by 182bps to 409.91% in 2025, then crashed by -216bps to 473.47% in 2026.
  • Business Quant data shows FCF Margin for PRLD at 473.47% in Q1 2026, 409.91% in Q4 2025, and 294.08% in Q3 2025.